We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.23 | -0.18% | 129.89 | 131.05 | 129.63 | 131.05 | 2,493,070 | 18:54:12 |
From Apr 2019 to Apr 2024
By Peter Loftus
The U.S. Food and Drug Administration on Tuesday approved Merck & Co.'s Keytruda drug to treat tumors with a certain genetic defect -- the first time the agency has cleared a cancer drug for a use not tied to the site of a tumor.
The FDA approved Keytruda to treat advanced solid tumors with genetic defects known as "microsatellite instability" or "mismatch repair" deficiencies. A study showed the drug shrank tumors in a significant number of patients with colorectal and 14 other cancer types that had the genetic defect.
Merck's Keytruda, which works by harnessing the body's immune system to attack tumors, has previously been approved to treat several site-specific tumors, including those of the skin and lung.
Write to Peter Loftus at peter.loftus@wsj.com
(END) Dow Jones Newswires
May 23, 2017 16:04 ET (20:04 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
